ArticleSeminars in hematology2023
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa.
Article in Seminars in hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 28 citations in OpenAlex.
- Global research trends and influential contributions in sickle cell disease: a bibliometric analysis of the top 100 cited papers.Journal of community genetics · 2026Review
- Article
- Analgesic Utilization Pattern and Cost of Managing Children with Sickle Cell Diseases: a Retrospective Single-site Audit.Journal of racial and ethnic health disparities · 2026Article
- Continuum of care after newborn screening for sickle cell disease: Multinational evidence from a systematic review and meta-analysis.British journal of haematology · 2026Article
- Barriers to sickle cell disease care: a biopsychosocial analysis mapped to the standards of care guidelines by the sickle pan African research consortium.Journal of public health (Oxford, England) · 2026Article
- Newborn Screening for Hemoglobinopathies and Thalassemias: Brief History, Recent Activities, and Global Status-2026.International journal of neonatal screening · 2026Review
- Strategies and innovations in hypertension management for sickle cell patients: A narrative review.Medicine · 2026Review
- From policy to practice: World Health Organization's contribution to safer blood transfusions in Africa for sickle cell management - a review.Annals of medicine and surgery (2012) · 2026Review
- Emerging Therapies for Sickle Cell Disease: From Symptom Management to Curative Gene Therapy.Cureus · 2025Review
- Level of Healthcare Facility and Psychosocial Factors Influence Perceived Self-Efficacy for Appropriate Use of Hydroxyurea: Experience from Caregivers of Children with Sickle Cell Disease in Tanzania.Healthcare (Basel, Switzerland) · 2025Article
- Thalassemia in Sub-Saharan Africa: epidemiology, diagnosis, and management - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- How to democratize cell and gene therapy: A global approach.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Building capacity for pediatric hematological diseases in Sub-Saharan Africa.Blood advances · 2025Review
- Article
- Feasibility analysis of the SICKLECHECK™ test kit for rapid screening of sickle cell disease at a County Referral Hospital in Kenya.African journal of laboratory medicine · 2025Article
- Newborn screening for sickle cell disease in Caluquembe, southwestern Angola, 2024-2025.PloS one · 2025Article
- Changes in haematological indices among children with sickle cell disease on hydroxyurea treatment for at least 1 year: A cohort study.PloS one · 2025Article
- Caregivers' beliefs about hydroxyurea influence its usage among children with sickle cell disease: a cross-sectional study in Dar-es-Salaam, Tanzania.The Pan African medical journal · 2025Article
- Evolving Landscape of Sickle Cell Anemia Management in Africa: A Critical Review.Tropical medicine and infectious disease · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Sickle cell disease (SCD) is the most common life-threatening monogenic disorder in the world. The disease is highly prevalent in malaria endemic areas with over 75% of patients residing in Sub-Saharan Africa (SSA). It is estimated that, without proper care, up to 90% of children with SCD will not celebrate their fifth birthday. Early identification and enrolment into comprehensive care has been shown to reduce the morbidity and mortality related with SCD complications. However, due to resource constraints, the SSA is yet to implement universal newborn screening programs for SCD. Furthermore, care for patients with SCD in the region is hampered by the shortage of qualified healthcare workers, lack of guidelines for the clinical management of SCD, limited infrastructure for inpatient and outpatient care, and limited access to blood and disease modifying drugs such as Hydroxyurea which contribute to poor clinical outcomes. Curative options such as bone marrow transplant and gene therapy are expensive and not available in many SSA countries. In addressing these challenges, various initiatives are ongoing in SSA which aim to enhance awareness on SCD, improve patient identification and retention to care, harmonize the standards of care for SCD, improve the skills of healthcare workers and conduct research on pertinent areas in SCD in the SSA context. Fortifying these measures is paramount to improving the outcomes of SCD in SSA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.